GlassScriptPhysician profile
Vimesh Akotia
NPI 1972524197
$2,032.30
in general payments reported to CMS, 2019-2025
10 companies · $219 in 2025
The $219 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $95.04 · 2023: $14.32 · 2024: $1,704 · 2025: $219.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,263 · Food and Beverage: $675.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,262.68 |
| Food and Beverage | $674.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Uk Limited | $1,447.01 | 2024 | Saphnelo |
| Janssen Biotech, INC. | $225.49 | 2024-2025 | Tremfya |
| Abbvie INC. | $123.18 | 2024 | |
| Radius Health, INC. | $95.04 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.84 | 2024 | Ofev, Cyltezo |
| Almatica Pharma LLC | $26.52 | 2024 | Teriparatide |
| Astrazeneca Pharmaceuticals LP | $24.71 | 2024 | Saphnelo |
| Depuy Synthes Sales INC. | $17.03 | 2025 | Monovisc, Orthovisc |
| Ibsa Pharma INC. | $14.32 | 2023 | Tirosint, Licart |
| Alvogen INC | $13.16 | 2024 | Teriparatide |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vimesh Akotia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.